Key result
Twice-daily low molecular weight heparin significantly reduced the incidence of venous thromboembolism compared to once-daily dosing (0% vs 9.09%, P=0.032) in patients following esophagectomy.
Why the study?
Does twice-daily nadroparin calcium reduce the incidence of venous thromboembolism compared to once-daily dosing in patients undergoing esophagectomy?
RCT (n=111)
Double-blind
Computer-generated list of random numbers
No
Does twice-daily nadroparin calcium reduce the incidence of venous thromboembolism compared to once-daily dosing in patients undergoing esophagectomy?
Absolute Event Rate: 0% vs 9.09%
p-value: p=0.032
Twice-daily low molecular weight heparin provides more effective VTE prophylaxis than once-daily dosing without increasing bleeding risk in patients undergoing esophagectomy.
No takes yet. Share an insight, caveat, or question.
Twice-daily LMWH reduces post-esophagectomy VTE versus once-daily dosing; extends RCT evidence supporting intensified prophylaxis in esophageal cancer.
Song et al. (2015) conducted an RCT in Esophageal cancer undergoing esophagectomy (n=111). Low molecular weight heparin (nadroparin calcium) vs. 4,100 AxaIU once-daily plus placebo was evaluated on Incidence of venous thromboembolism (VTE) at 7th postoperative day (p=0.032). Twice-daily low molecular weight heparin significantly reduced the incidence of venous thromboembolism compared to once-daily dosing (0% vs 9.09%, P=0.032) in patients following esophagectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: